(Length of Presentation: 12 min)

Phillip Koo, MD presents the impact of advanced imaging in prostate cancer and his imaging strategy for the M0 CRPC patient.  His discussion is shaped around the impact next-generation imaging has had on prostate cancer and M0 CRPC with the approvals of Axumin PET/CT, PSMA PET/CT, and Choline PET/CT, and improving the image quality compared to CT and Bone Scan. He details how these new tools have changed practice, the questions they have risen, and how the landscape has changed with the recent studies of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN) and Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER).


Content Referenced in Presentation

Watch: First presentation of SPARTAN - A Phase 3 Double-blind, Randomized Study of Apalutamide (APA) versus Placebo in Patients with Nonmetastatic Castration-resistant Prostate Cancer (nmCRPC) - Eric Small

Watch: Meeting an Unmet Need in the Nonmetastatic Castration-Resistant Prostate Cancer Patient Population - Maha Hussain
Challenges and Recommendations for Early Identification of Metastatic Disease in Prostate Cancer - Abstract

Center of Excellence: CRPC with Bone Metastases - Daniel George

Felix Feng, MD presentation at: ASCO GU 2018- Management of Oligometastatic Prostate Cancer From Imaging to Therapy

Biography:
Phillip J. Koo, MD, FACS